EA039404B1 - Аттенуированный вирус ньюкаслской болезни (ndv) штамма 73т для лечения неоплазии, способ селективного цитолиза опухолевых клеток и способ индуцирования регресса опухоли с его использованием - Google Patents
Аттенуированный вирус ньюкаслской болезни (ndv) штамма 73т для лечения неоплазии, способ селективного цитолиза опухолевых клеток и способ индуцирования регресса опухоли с его использованием Download PDFInfo
- Publication number
- EA039404B1 EA039404B1 EA201690425A EA201690425A EA039404B1 EA 039404 B1 EA039404 B1 EA 039404B1 EA 201690425 A EA201690425 A EA 201690425A EA 201690425 A EA201690425 A EA 201690425A EA 039404 B1 EA039404 B1 EA 039404B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- virus
- ndv
- tumor
- newcastle disease
- Prior art date
Links
- 241000711404 Avian avulavirus 1 Species 0.000 title claims abstract description 258
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 212
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 36
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 30
- 230000001939 inductive effect Effects 0.000 title claims abstract description 8
- 230000009826 neoplastic cell growth Effects 0.000 title claims description 26
- 241000700605 Viruses Species 0.000 claims abstract description 237
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims abstract description 51
- 230000000174 oncolytic effect Effects 0.000 claims abstract description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 266
- 108700019146 Transgenes Proteins 0.000 claims description 65
- 201000011510 cancer Diseases 0.000 claims description 49
- 238000003776 cleavage reaction Methods 0.000 claims description 36
- 230000007017 scission Effects 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 35
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 19
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 19
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 108091026890 Coding region Proteins 0.000 claims description 17
- 108010002350 Interleukin-2 Proteins 0.000 claims description 16
- 102000000588 Interleukin-2 Human genes 0.000 claims description 16
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 102000046157 human CSF2 Human genes 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 108010012236 Chemokines Proteins 0.000 claims description 9
- 102000019034 Chemokines Human genes 0.000 claims description 9
- 210000004072 lung Anatomy 0.000 claims description 9
- 210000001672 ovary Anatomy 0.000 claims description 8
- 108091029795 Intergenic region Proteins 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 102000003812 Interleukin-15 Human genes 0.000 claims description 4
- 108090000172 Interleukin-15 Proteins 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 108010074108 interleukin-21 Proteins 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 210000003932 urinary bladder Anatomy 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 17
- 230000007026 protein scission Effects 0.000 abstract description 8
- 230000001717 pathogenic effect Effects 0.000 abstract description 6
- 244000144977 poultry Species 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 description 77
- 230000009089 cytolysis Effects 0.000 description 57
- 206010057248 Cell death Diseases 0.000 description 54
- 241000287828 Gallus gallus Species 0.000 description 53
- 235000013330 chicken meat Nutrition 0.000 description 53
- 210000003501 vero cell Anatomy 0.000 description 52
- 102000004169 proteins and genes Human genes 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 47
- 235000013601 eggs Nutrition 0.000 description 45
- 239000013612 plasmid Substances 0.000 description 45
- 239000000203 mixture Substances 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 43
- 230000000694 effects Effects 0.000 description 41
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 38
- 208000015181 infectious disease Diseases 0.000 description 38
- 239000002299 complementary DNA Substances 0.000 description 37
- 230000004614 tumor growth Effects 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 33
- 238000003556 assay Methods 0.000 description 32
- 230000003612 virological effect Effects 0.000 description 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 24
- 238000003780 insertion Methods 0.000 description 24
- 230000037431 insertion Effects 0.000 description 24
- 241000059175 Pigeon paramyxovirus 1 Species 0.000 description 23
- 230000012010 growth Effects 0.000 description 22
- 108700026244 Open Reading Frames Proteins 0.000 description 21
- 102000004142 Trypsin Human genes 0.000 description 21
- 108090000631 Trypsin Proteins 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- 239000012588 trypsin Substances 0.000 description 21
- 230000001018 virulence Effects 0.000 description 21
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 20
- 230000007918 pathogenicity Effects 0.000 description 20
- 230000010076 replication Effects 0.000 description 20
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- 239000012634 fragment Substances 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 230000002779 inactivation Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 108020000999 Viral RNA Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 238000001243 protein synthesis Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 11
- 201000008808 Fibrosarcoma Diseases 0.000 description 11
- 101150062031 L gene Proteins 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 229910052698 phosphorus Inorganic materials 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 239000001509 sodium citrate Substances 0.000 description 11
- 230000014616 translation Effects 0.000 description 11
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 11
- 229940038773 trisodium citrate Drugs 0.000 description 11
- 230000029812 viral genome replication Effects 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- 210000005170 neoplastic cell Anatomy 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 244000309459 oncolytic virus Species 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 230000009261 transgenic effect Effects 0.000 description 10
- 241000271566 Aves Species 0.000 description 9
- 241000408533 Lento Species 0.000 description 9
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 9
- 101710137500 T7 RNA polymerase Proteins 0.000 description 9
- 238000011717 athymic nude mouse Methods 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000006819 RNA synthesis Effects 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000013413 tumor xenograft mouse model Methods 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 238000003570 cell viability assay Methods 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000007505 plaque formation Effects 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241001559185 Mammalian rubulavirus 5 Species 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000002601 intratumoral effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000007444 viral RNA synthesis Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000712079 Measles morbillivirus Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 208000007660 Residual Neoplasm Diseases 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101150008820 HN gene Proteins 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000000531 effect on virus Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 238000007808 Cell invasion assay Methods 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 101150066002 GFP gene Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101001034843 Mus musculus Interferon-induced transmembrane protein 1 Proteins 0.000 description 2
- 229940124160 Myc inhibitor Drugs 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 101710181008 P protein Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 101710177166 Phosphoprotein Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 108010029389 Simplexvirus glycoprotein B Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 108091034135 Vault RNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- -1 antibody Chemical class 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108700030515 omomyc Proteins 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 241000724287 Apple mosaic virus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 241001353878 Canine parainfluenza virus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102000047934 Caspase-3/7 Human genes 0.000 description 1
- 108700037887 Caspase-3/7 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101150034814 F gene Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 108700004031 HN Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000012428 Hematopoietic Cell Growth Factors Human genes 0.000 description 1
- 108010022580 Hematopoietic Cell Growth Factors Proteins 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 1
- 101710194995 Interleukin-12 subunit alpha Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000000594 effect on fusion Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008011 embryonic death Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 230000009463 immunological memory response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000011873 mild conjunctivitis Diseases 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000013718 rectal benign neoplasm Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361873039P | 2013-09-03 | 2013-09-03 | |
| PCT/EP2014/068619 WO2015032755A1 (en) | 2013-09-03 | 2014-09-02 | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201690425A1 EA201690425A1 (ru) | 2016-08-31 |
| EA039404B1 true EA039404B1 (ru) | 2022-01-24 |
Family
ID=51492938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690425A EA039404B1 (ru) | 2013-09-03 | 2014-09-02 | Аттенуированный вирус ньюкаслской болезни (ndv) штамма 73т для лечения неоплазии, способ селективного цитолиза опухолевых клеток и способ индуцирования регресса опухоли с его использованием |
| EA202191926A EA202191926A3 (ru) | 2013-09-03 | 2014-09-02 | Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191926A EA202191926A3 (ru) | 2013-09-03 | 2014-09-02 | Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10519426B2 (enExample) |
| EP (3) | EP4101457A1 (enExample) |
| JP (2) | JP6557234B2 (enExample) |
| KR (2) | KR102285894B1 (enExample) |
| CN (2) | CN106163532B (enExample) |
| AU (2) | AU2014317215C1 (enExample) |
| CA (1) | CA2922071C (enExample) |
| CY (2) | CY1121993T1 (enExample) |
| DK (2) | DK3508209T3 (enExample) |
| EA (2) | EA039404B1 (enExample) |
| ES (2) | ES2708755T3 (enExample) |
| HK (2) | HK1231393A1 (enExample) |
| HR (2) | HRP20190250T1 (enExample) |
| HU (1) | HUE042382T2 (enExample) |
| LT (2) | LT3508209T (enExample) |
| ME (1) | ME03345B (enExample) |
| MX (2) | MX367768B (enExample) |
| PL (2) | PL3041490T3 (enExample) |
| PT (2) | PT3041490T (enExample) |
| RS (2) | RS58332B1 (enExample) |
| SI (2) | SI3508209T1 (enExample) |
| SM (2) | SMT202200214T1 (enExample) |
| TR (1) | TR201902073T4 (enExample) |
| TW (1) | TWI653334B (enExample) |
| WO (1) | WO2015032755A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5603012B2 (ja) | 2005-12-02 | 2014-10-08 | トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ | 非天然表面タンパク質を提示するキメラウイルス及びその使用 |
| EP2393921B1 (en) | 2009-02-05 | 2015-07-15 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses and uses thereof |
| PE20151921A1 (es) | 2013-03-14 | 2015-12-26 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle y usos de los mismos |
| PL3041490T3 (pl) * | 2013-09-03 | 2019-05-31 | Medimmune Ltd | Kompozycje zawierające atenuowany wirus choroby Newcastle i sposoby ich stosowania w leczeniu neoplazji |
| AU2015222685A1 (en) | 2014-02-27 | 2016-09-08 | Viralytics Limited | Combination method for treatment of cancer |
| WO2016176510A1 (en) * | 2015-04-28 | 2016-11-03 | University Of Georgia Research Foundation, Inc. | Piv5-based amplifying virus-like particles |
| EP3400291B2 (en) | 2016-01-08 | 2024-02-28 | Replimune Limited | Engineered virus |
| EP3246410A1 (en) * | 2016-05-19 | 2017-11-22 | Klinikum rechts der Isar der Technischen Universität München | Vsv/ndv hybrid viruses for oncolytic therapy of cancer |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| KR101964610B1 (ko) * | 2017-03-13 | 2019-04-03 | 대한민국 | 신규한 종양용해성 바이러스 및 이의 용도 |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CN107254450A (zh) * | 2017-07-20 | 2017-10-17 | 扬州大学 | 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法 |
| CN108486279A (zh) * | 2017-09-21 | 2018-09-04 | 山东省农业科学院家禽研究所 | 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法 |
| EP3552608A1 (en) * | 2018-04-09 | 2019-10-16 | Rapo Yerape B.H. Ltd | Increased activity of oncoloytic newcastle disease virus |
| CN112601547A (zh) | 2018-06-21 | 2021-04-02 | 雷普利穆内有限公司 | 使用溶瘤病毒的治疗 |
| CA3106170A1 (en) * | 2018-07-13 | 2020-01-16 | Icahn School Of Medicine At Mount Sinai | Apmv and uses thereof for the treatment of cancer |
| EP3837277A4 (en) | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
| CN110859968A (zh) * | 2019-11-21 | 2020-03-06 | 四川安可康生物医药有限公司 | 激活对肿瘤的系统免疫反应的基因生物药物 |
| US20240245805A1 (en) * | 2020-03-20 | 2024-07-25 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| CN115197949A (zh) * | 2021-04-13 | 2022-10-18 | 江苏康缘瑞翱生物医药科技有限公司 | 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途 |
| KR20240001198A (ko) * | 2021-04-26 | 2024-01-03 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Apmv hn 및 f 단백질을 발현하는 키메라 뉴캐슬병 바이러스 |
| CA3161532A1 (en) * | 2021-06-03 | 2022-12-03 | University Of Guelph | Engineered newcastle disease virus vector and uses thereof |
| CN121263205A (zh) * | 2023-02-06 | 2026-01-02 | 塞维卡有限责任公司 | 修饰的piv5疫苗载体：制造方法和用途 |
| WO2025116613A1 (ko) * | 2023-11-29 | 2025-06-05 | 주식회사 카브 | 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물 |
| CN120290572A (zh) * | 2025-04-09 | 2025-07-11 | 梅尔顿(深圳)生物医药技术有限公司 | 一种重组新城疫病毒及其制备方法和在抗肿瘤中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001020989A1 (en) * | 1999-09-22 | 2001-03-29 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| WO2009095167A1 (en) * | 2008-01-29 | 2009-08-06 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| WO2009101149A2 (en) * | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Anti-tumour effective paramyxovirus |
| WO2010091262A1 (en) * | 2009-02-05 | 2010-08-12 | Mount Sinai School Of Medicine Of New York University | Chimeric newcastle disease viruses and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7724558B1 (en) * | 1999-03-19 | 2010-05-25 | Nec Corporation | Magnetic signal transmission line |
| KR100801180B1 (ko) * | 2006-09-26 | 2008-02-05 | 주식회사 고려비엔피 | 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신 |
| PE20151921A1 (es) * | 2013-03-14 | 2015-12-26 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle y usos de los mismos |
| PL3041490T3 (pl) * | 2013-09-03 | 2019-05-31 | Medimmune Ltd | Kompozycje zawierające atenuowany wirus choroby Newcastle i sposoby ich stosowania w leczeniu neoplazji |
| CN109099045A (zh) * | 2018-10-30 | 2018-12-28 | 浙江斯泰新材料科技股份有限公司 | 防松锁固型螺钉 |
-
2014
- 2014-09-02 PL PL14761317T patent/PL3041490T3/pl unknown
- 2014-09-02 CA CA2922071A patent/CA2922071C/en active Active
- 2014-09-02 SM SM20220214T patent/SMT202200214T1/it unknown
- 2014-09-02 PT PT14761317T patent/PT3041490T/pt unknown
- 2014-09-02 ME MEP-2019-40A patent/ME03345B/me unknown
- 2014-09-02 DK DK18188565.8T patent/DK3508209T3/da active
- 2014-09-02 HU HUE14761317A patent/HUE042382T2/hu unknown
- 2014-09-02 TR TR2019/02073T patent/TR201902073T4/tr unknown
- 2014-09-02 EP EP22160157.8A patent/EP4101457A1/en not_active Withdrawn
- 2014-09-02 EA EA201690425A patent/EA039404B1/ru unknown
- 2014-09-02 JP JP2016537333A patent/JP6557234B2/ja not_active Expired - Fee Related
- 2014-09-02 ES ES14761317T patent/ES2708755T3/es active Active
- 2014-09-02 RS RS20190176A patent/RS58332B1/sr unknown
- 2014-09-02 DK DK14761317.8T patent/DK3041490T3/en active
- 2014-09-02 HR HRP20190250TT patent/HRP20190250T1/hr unknown
- 2014-09-02 ES ES18188565T patent/ES2914577T3/es active Active
- 2014-09-02 US US14/916,102 patent/US10519426B2/en active Active
- 2014-09-02 SI SI201431957T patent/SI3508209T1/sl unknown
- 2014-09-02 KR KR1020167008307A patent/KR102285894B1/ko not_active Expired - Fee Related
- 2014-09-02 RS RS20220481A patent/RS63291B1/sr unknown
- 2014-09-02 PT PT181885658T patent/PT3508209T/pt unknown
- 2014-09-02 HK HK17105137.4A patent/HK1231393A1/zh unknown
- 2014-09-02 CN CN201480048630.4A patent/CN106163532B/zh active Active
- 2014-09-02 KR KR1020217012332A patent/KR102310692B1/ko not_active Expired - Fee Related
- 2014-09-02 EP EP18188565.8A patent/EP3508209B1/en active Active
- 2014-09-02 AU AU2014317215A patent/AU2014317215C1/en not_active Ceased
- 2014-09-02 EP EP14761317.8A patent/EP3041490B1/en active Active
- 2014-09-02 SM SM20190094T patent/SMT201900094T1/it unknown
- 2014-09-02 MX MX2016002771A patent/MX367768B/es active IP Right Grant
- 2014-09-02 WO PCT/EP2014/068619 patent/WO2015032755A1/en not_active Ceased
- 2014-09-02 SI SI201431082T patent/SI3041490T1/sl unknown
- 2014-09-02 CN CN202010064863.0A patent/CN111944767A/zh active Pending
- 2014-09-02 HR HRP20220653TT patent/HRP20220653T1/hr unknown
- 2014-09-02 PL PL18188565T patent/PL3508209T3/pl unknown
- 2014-09-02 HK HK16114099.3A patent/HK1225643B/en not_active IP Right Cessation
- 2014-09-02 LT LTEP18188565.8T patent/LT3508209T/lt unknown
- 2014-09-02 EA EA202191926A patent/EA202191926A3/ru unknown
- 2014-09-02 LT LTEP14761317.8T patent/LT3041490T/lt unknown
- 2014-09-03 TW TW103130466A patent/TWI653334B/zh active
-
2016
- 2016-03-02 MX MX2019010364A patent/MX2019010364A/es unknown
-
2019
- 2019-02-08 CY CY20191100170T patent/CY1121993T1/el unknown
- 2019-06-24 AU AU2019204419A patent/AU2019204419B2/en not_active Ceased
- 2019-07-11 JP JP2019129161A patent/JP6862500B2/ja not_active Expired - Fee Related
- 2019-11-14 US US16/684,241 patent/US11471499B2/en active Active
-
2022
- 2022-05-25 CY CY20221100362T patent/CY1126790T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001020989A1 (en) * | 1999-09-22 | 2001-03-29 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| WO2009095167A1 (en) * | 2008-01-29 | 2009-08-06 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| WO2009101149A2 (en) * | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Anti-tumour effective paramyxovirus |
| WO2010091262A1 (en) * | 2009-02-05 | 2010-08-12 | Mount Sinai School Of Medicine Of New York University | Chimeric newcastle disease viruses and uses thereof |
Non-Patent Citations (5)
| Title |
|---|
| J. C. F. M. DORTMANS, ROTTIER P. J. M., KOCH G., PEETERS B. P. H.: "Passaging of a Newcastle disease virus pigeon variant in chickens results in selection of viruses with mutations in the polymerase complex enhancing virus replication and virulence", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY ¬ETC.|, vol. 92, no. 2, 1 February 2011 (2011-02-01), pages 336 - 345, XP055155911, ISSN: 00221317, DOI: 10.1099/vir.0.026344-0 * |
| JANKE M, ET AL: "Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.", GENE THERAPY, NATURE PUBLISHING GROUP, LONDON, GB, vol. 14, no. 23, 1 December 2007 (2007-12-01), GB , pages 1639 - 1649, XP002606261, ISSN: 0969-7128, DOI: 10.1038/SJ.GT.3303026 * |
| JOS CFM DORTMANS;GUUS KOCH;PETER JM ROTTIER;BEN PH PEETERS: "Virulence of newcastle disease virus: what is known so far?", VETERINARY RESEARCH, BIOMED CENTRAL LTD, LONDON, UK, vol. 42, no. 1, 23 December 2011 (2011-12-23), London, UK , pages 122, XP021130364, ISSN: 1297-9716, DOI: 10.1186/1297-9716-42-122 * |
| PHILIPPE FOURNIER, VOLKER SCHIRRMACHER: "Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host", BIOLOGY, vol. 2, no. 3, pages 936 - 975, XP055155919, DOI: 10.3390/biology2030936 * |
| S. SAMAL, S. KUMAR, S. K. KHATTAR: "A single amino acid change, Q114R, in the cleavage-site sequence of Newcastle disease virus fusion protein attenuates viral replication and pathogenicity", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY ¬ETC.|, vol. 92, no. 10, 1 October 2011 (2011-10-01), pages 2333 - 2338, XP055156082, ISSN: 00221317, DOI: 10.1099/vir.0.033399-0 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11471499B2 (en) | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia | |
| HK1225643A1 (en) | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia | |
| US11793844B2 (en) | Virus for treatment of tumor | |
| CA3097306A1 (en) | Coxsackie virus b for treating tumors | |
| Javaheri et al. | Avian paramyxovirus 4 antitumor activity leads to complete remissions and long-term protective memory in preclinical melanoma and colon carcinoma models | |
| JP7373168B2 (ja) | 腫瘍を治療するためのエコーウイルス | |
| HK40011356B (en) | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia | |
| HK40011356A (en) | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia | |
| Masoud et al. | Engineered Newcastle disease virus expressing the haemagglutinin protein of H9N2 confers protection against challenge infections in chickens | |
| US20220339222A1 (en) | New oncolytic newcastle disease viruses and recombinant ndv strains | |
| HK40042398A (en) | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia | |
| EP3868876A1 (en) | New oncolytic newcastle disease viruses and recombinant ndv strains | |
| Mustafa | In Vitro and Preclinical Evaluation of Newcastle Disease Virus Strain V4upm as an Oncolytic Virus Candidate for Novel Human Malignant Glioma Therapy |